127 related articles for article (PubMed ID: 23389364)
1. Clinical value of vascular endothelial growth factor and endostatin in urine for diagnosis of bladder cancer.
Cheng D; Liang B; Li Y
Tumori; 2012 Nov; 98(6):762-7. PubMed ID: 23389364
[TBL] [Abstract][Full Text] [Related]
2. CXCL5 is a potential diagnostic and prognostic marker for bladder cancer patients.
Zhu X; Qiao Y; Liu W; Wang W; Shen H; Lu Y; Hao G; Zheng J; Tian Y
Tumour Biol; 2016 Apr; 37(4):4569-77. PubMed ID: 26503215
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection.
Urquidi V; Goodison S; Kim J; Chang M; Dai Y; Rosser CJ
Urology; 2012 May; 79(5):1185.e1-6. PubMed ID: 22386755
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of the VEGF level in urinary bladder carcinoma.
Sankhwar M; Sankhwar SN; Abhishek A; Rajender S
Cancer Biomark; 2015; 15(4):349-55. PubMed ID: 25792473
[TBL] [Abstract][Full Text] [Related]
5. The diagnostic efficacy of urinary TGF-beta1 and VEGF in bladder cancer: comparison with voided urine cytology.
Eissa S; Salem AM; Zohny SF; Hegazy MG
Cancer Biomark; 2007; 3(6):275-85. PubMed ID: 18048965
[TBL] [Abstract][Full Text] [Related]
6. Serum endostatin levels correlate with enhanced extracellular matrix degradation and poor patients' prognosis in bladder cancer.
Szarvas T; László V; Vom Dorp F; Reis H; Szendröi A; Romics I; Tilki D; Rübben H; Ergün S
Int J Cancer; 2012 Jun; 130(12):2922-9. PubMed ID: 21815140
[TBL] [Abstract][Full Text] [Related]
7. A multi-analyte assay for the non-invasive detection of bladder cancer.
Goodison S; Chang M; Dai Y; Urquidi V; Rosser CJ
PLoS One; 2012; 7(10):e47469. PubMed ID: 23094052
[TBL] [Abstract][Full Text] [Related]
8. Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates.
Crew JP; O'Brien T; Bicknell R; Fuggle S; Cranston D; Harris AL
J Urol; 1999 Mar; 161(3):799-804. PubMed ID: 10022687
[TBL] [Abstract][Full Text] [Related]
9. Prognostic values of VEGF and endostatin with malignant pleural effusions in patients with lung cancer.
Zhang Y; Yu LK; Lu GJ; Xia N; Xie HY; Hu W; Hao KK; Xu CH; Qian Q
Asian Pac J Cancer Prev; 2014; 15(19):8435-40. PubMed ID: 25339042
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of vascular endothelial growth factor and endostatin levels in the differential diagnosis of malignant and benign ascites.
Cheng D; Liang B; Kong H
Med Oncol; 2012 Jun; 29(2):1397-402. PubMed ID: 21556933
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment serum endostatin as a prognostic indicator in metastatic gastric carcinoma.
Woo IS; Kim KA; Jeon HM; Hong SH; Rho SY; Koh SJ; Lee MA; Byun JH; Kang JH; Hong YS; Lee KS; Cho CS; Choi MG; Chung IS
Int J Cancer; 2006 Dec; 119(12):2901-6. PubMed ID: 16998835
[TBL] [Abstract][Full Text] [Related]
12. Elevated serum endostatin levels are associated with poor survival in patients with advanced-stage nasopharyngeal carcinoma.
Mo HY; Luo DH; Qiu HZ; Liu H; Chen QY; Tang LQ; Zhong ZL; Huang PY; Zhao ZJ; Zhang CQ; Zhang Y; Mai HQ
Clin Oncol (R Coll Radiol); 2013 May; 25(5):308-17. PubMed ID: 23290342
[TBL] [Abstract][Full Text] [Related]
13. Correlations between serum levels of vascular endothelial growth factor and endostatin with clinical pathological characteristics of patients with gastrointestinal cancers.
Li M; Liu F; Sun P; Gao Y; Chen H; Liu H; Wang M; Chen J; Zhao Y
Hepatogastroenterology; 2012 Sep; 59(118):1865-8. PubMed ID: 22819906
[TBL] [Abstract][Full Text] [Related]
14. Distinct DNA methylation epigenotypes in bladder cancer from different Chinese sub-populations and its implication in cancer detection using voided urine.
Chen PC; Tsai MH; Yip SK; Jou YC; Ng CF; Chen Y; Wang X; Huang W; Tung CL; Chen GC; Huang MM; Tong JH; Song EJ; Chang DC; Hsu CD; To KF; Shen CH; Chan MW
BMC Med Genomics; 2011 May; 4():45. PubMed ID: 21599969
[TBL] [Abstract][Full Text] [Related]
15. [Clinical evaluation of BTAstat, NMP22, HA, survivin, CD44v6, vEGF and VUC in bladder cancer diagnosis].
Sun Y; He H; Ma Q; Wang XY; Yang L; He DL
Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(35):2507-12. PubMed ID: 16321281
[TBL] [Abstract][Full Text] [Related]
16. Comparison of telomerase activity and matrix metalloproteinase-9 in voided urine and bladder wash samples as a useful diagnostic tool for bladder cancer.
Eissa S; Labib RA; Mourad MS; Kamel K; El-Ahmady O
Eur Urol; 2003 Dec; 44(6):687-94. PubMed ID: 14644121
[TBL] [Abstract][Full Text] [Related]
17. Urine tenascin‑C is an independent risk factor for bladder cancer patients.
Guan Z; Zeng J; Wang Z; Xie H; Lv C; Ma Z; Xu S; Wang X; He D; Li L
Mol Med Rep; 2014 Mar; 9(3):961-6. PubMed ID: 24366195
[TBL] [Abstract][Full Text] [Related]
18. Imbalance between vascular endothelial growth factor and endostatin correlates with the prognosis of operable non-small cell lung cancer.
Hu Y; Hu MM; Shi GL; Han Y; Li BL
Eur J Surg Oncol; 2014 Sep; 40(9):1136-42. PubMed ID: 24998915
[TBL] [Abstract][Full Text] [Related]
19. Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group.
Schips L; Dalpiaz O; Lipsky K; Langner C; Rehak P; Puerstner P; Pummer K; Zigeuner R
Eur Urol; 2007 Jan; 51(1):168-73; discussion 174. PubMed ID: 16844285
[TBL] [Abstract][Full Text] [Related]
20. Placental Growth Factor in Bladder Cancer Compared to the Diagnostic Accuracy and Prognostic Performance of Vascular Endothelial Growth Factor A.
Soukup V; Čapoun O; Pešl M; Sobotka R; Vávřová L; Hanuš T; Zima T; Kalousová M
Anticancer Res; 2018 Jan; 38(1):239-246. PubMed ID: 29277778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
